Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Baer

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Nilotinib risk evaluation and mitigation strategyMaria Baer
Leukemia & Lymphoma|May 9, 2008
T/B and not T/B: high frequency of B-cell dyscrasias in T-LGL leukemiaAttaphol Pawarode, Maria Baer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Nilotinib risk evaluation and mitigation strategyMaria Baer
Leukemia & Lymphoma|May 9, 2008
T/B and not T/B: high frequency of B-cell dyscrasias in T-LGL leukemiaAttaphol Pawarode, Maria Baer
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
Pageof 1